Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
- Wednesday, January 19, 2022, 7:05
- Finance
- Add a comment
Purchase of Assets and Related Global Commercialization Rights for Oral 9-cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. Clinical Stage Asset Has Potential for First Approved Oral Therapy for Leber’s Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP) Caused by…
About the Author
adminasapcorp has written 41562 stories on this site.